ARCHIVES

NCI Programs: NCI Drug Screening To Take More Targeted Approach; BSA Okays Plan To Support New MA Contracts

This article is from The Cancer Letter archive.

Vol. 24 No. 13 | April 3, 1998

Download PDF Visit The Full Archive

Related Articles

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

May 30, 2014

NIH Says Its Probe Found Charges Of Double Payment “Basically Correct”

October 23, 1981

Budget Year

November 12, 2010

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004

NIH Inquiry Finds No Impropriety In Treatment of Teddy DeVita

April 9, 1976

Medical Oncology Fosters Long Term Relationships

May 5, 1989